Company / Cash & Equivalents
ALNYLAM PHARMACEUTICALS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.7B
FY2025
5-year range
$496.6M / $1.7B
FY2021-FY2025
Trend
+71.5%
vs FY2024
Sector context
#13 of 207
Health Care
What the data says
Among 207 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the top 6% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $194M in FY2016 to $1.7B in FY2025.
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of +24.8%. Top quartile in the Health Care sector.
Improved from $813M to $1.7B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +26.4%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
+147.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 71.5% year-over-year.
- Ranks #13 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | +71.5% |
| FY2024 | $966.4M | +18.9% |
| FY2023 | $812.7M | -0.9% |
| FY2022 | $820.0M | +65.1% |
| FY2021 | $496.6M | -9.2% |
| FY2020 | $547.2M | +30.2% |
| FY2019 | $420.1M | -34.9% |
| FY2018 | $645.4M | +0.0% |
| FY2017 | $645.4M | +233.3% |
| FY2016 | $193.6M | +7.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026